Amgen Recalls Sensipar and Corlanor Lots Over Manufacturing Defects

Key Facts

In a move highlighting the regulatory challenges facing major pharmaceutical players, Amgen has announced a voluntary recall of certain Sensipar and Corlanor tablet lots from the US market. According to reports, this decision followed the identification of manufacturing deviations and the presence of foreign substances within these lots, prompting the FDA to classify the event as a Class II recall. This development underscores the critical nature of operational oversight in the healthcare sector to ensure the integrity of medicinal products.

This crisis emerges as the biotechnology sector faces increased scrutiny over supply chain quality, with peers such as Pfizer and Novartis experiencing similar manufacturing hurdles in recent periods. While Amgen reported robust revenue in its prior quarter, the costs associated with recalls and regulatory compliance may pressure operating margins. Per market data, investors are closely monitoring how these deviations impact the company's corporate reputation and its ability to defend market share against generic competitors.

Regarding market performance, AMGN closed at $355.25 (close July 14, 2026), with the stock trading between a day low of $354.71 and a high of $358.86. Traders are looking ahead to the US Monetary Policy Report scheduled for July 10, 2026, which could influence broader market sentiment toward growth and healthcare equities. Focus remains on support levels near the recent daily lows to gauge the market's absorption of this regulatory setback.